Sagimet Biosciences Inc. (SGMT) Key Metrics
SGMT valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $568.7M
- Enterprise value
- $408.9M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 52.5
- Price / book
- 2.5 10-yr median 1.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 3.49
SGMT key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSGMT valuation Price multiples at each fiscal year-end price.
SGMT returns How much profit the business earns on the capital it uses.
SGMT per-share figures Results divided by the shares outstanding at year-end.
SGMT financial health Debt, liquidity and how easily interest is covered.
SGMT valuation history
SGMT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SGMT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SGMT price vs earnings per share
SGMT key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $191.5M | $141.1M | $98.6M | — | — | — | — |
| Enterprise value | $78.4M | −$10.1M | $3.8M | — | — | — | — |
| Price / sales | — | — | 49.3 | — | — | — | — |
| Price / book | 1.7 | 0.9 | 1.1 | — | — | — | — |
| EV / sales | — | — | 1.9 | — | — | — | — |
| Earnings yield | −26.7% | −32.3% | −28.3% | — | — | — | — |
| Free cash flow yield | −23.8% | −30.1% | −24.1% | — | — | — | — |
| Share price at fiscal year-end | $5.92 | $4.50 | $5.42 | — | — | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | $0.00 | $0.11 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$1.58 | −$1.45 | −$1.53 | −$1.38 | −$1.10 | −$0.51 | −$0.64 |
| Operating cash flow per share | −$1.41 | −$1.35 | −$1.31 | −$1.10 | −$0.98 | −$0.47 | −$0.48 |
| Free cash flow per share | −$1.41 | −$1.35 | −$1.31 | −$1.10 | −$0.98 | −$0.47 | −$0.48 |
| Cash per share | $3.50 | $4.82 | $5.22 | $1.46 | $2.56 | $3.10 | $0.46 |
| Book value per share | $3.44 | $4.97 | $5.01 | −$8.43 | −$7.14 | −$6.13 | −$5.65 |
| Tangible book value per share | $3.44 | $4.97 | $5.01 | −$8.43 | −$7.14 | −$6.13 | −$5.65 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | $0.00 | $0.00 | $0.00 | $0.01 | $0.02 | $0.01 | $0.02 |
| Shares outstanding | 32.3M | 31.4M | 18.2M | 22.2M | 22.2M | 22.2M | 22.2M |
| Change in shares outstanding | +3.2% | +72.3% | −17.9% | 0.0% | 0.0% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −38.2% | −36.9% | — | — | — | — | — |
| Return on assets (ROA) | −36.9% | −35.5% | −43.0% | −66.3% | −38.2% | −28.4% | −127.8% |
| Return on tangible assets | −43.8% | −28.4% | −28.8% | −92.3% | −41.4% | −16.5% | −127.8% |
| Financial health | |||||||
| Total debt | $78,000 | $78,000 | $65,000 | $211,000 | $348,000 | $210,000 | $341,000 |
| Cash & short-term investments | $113.1M | $151.2M | $94.9M | $32.3M | $56.7M | $68.7M | $10.2M |
| Net debt | −$113.0M | −$151.2M | −$94.8M | −$32.1M | −$56.4M | −$68.5M | −$9.9M |
| Debt / equity | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Debt / assets | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.03 |
| Current ratio | 22.82 | 34.30 | 17.09 | 6.21 | 24.04 | 35.99 | 5.21 |
| Quick ratio | 22.82 | 34.30 | 17.09 | 6.21 | 24.04 | 35.99 | 5.21 |
| Interest coverage | — | — | — | — | — | — | -221.2 |
| Working capital | $111.3M | $148.3M | $91.0M | $27.5M | $56.2M | $66.8M | $8.7M |
| Invested capital | −$1.7M | $4.6M | −$3.8M | −$219.1M | −$214.6M | −$204.4M | −$135.2M |
| Tangible asset value | $111.4M | $155.8M | $91.1M | −$186.9M | −$158.3M | −$135.9M | −$125.3M |
| Net current asset value | $111.3M | $148.3M | $91.0M | −$187.2M | −$158.6M | −$136.1M | −$125.7M |
| Graham net-net per share | $3.34 | $4.68 | $4.90 | −$8.46 | −$7.24 | −$6.14 | −$5.69 |
| Capital allocation | |||||||
| Capex / revenue | — | — | 0.0% | — | — | — | — |
| Capex / depreciation | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-based compensation / revenue | — | — | 249.5% | — | — | — | — |
| R&D / revenue | — | — | 988.9% | — | — | — | — |
| SG&A / revenue | — | — | 648.1% | — | — | — | — |
| Efficiency | |||||||
| Days payables outstanding | — | — | — | 2,647.7 | 1,735.1 | 2,519.7 | 4,973.1 |
| Payables turnover | — | — | 0.00 | 0.14 | 0.21 | 0.14 | 0.07 |
| Asset turnover | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $1.4M | $805,500 | $655,500 | $943,000 | $637,000 | $856,000 | $1.2M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from SGMT's annual financial statements (latest annual report filed March 11, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SGMT valuation and financial ratios
Sagimet Biosciences earned a return on equity of −38.2% in fiscal 2025. It ended the year with $0.1 million of debt and $113.1 million in cash and short-term investments, a net cash position of $113.0 million. The share count rose 45.9% from 22.2M to 32.3M over 6 years.
See the SGMT income statement, the SGMT chart for price history, or the SGMT stock overview for the latest quote and news.
SGMT key metrics FAQ
What is Sagimet Biosciences's return on equity?
Sagimet Biosciences's return on equity (ROE) was −38.2% in fiscal 2025: net income of -$51.0 million on average shareholders' equity of $133.6 million.
How much debt does Sagimet Biosciences have?
Sagimet Biosciences had total debt of $0.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Sagimet Biosciences's free cash flow yield?
Sagimet Biosciences generated -$45.6 million of free cash flow in fiscal 2025, a free cash flow yield of −23.8% on its market value at year-end ($191.5 million).
What is Sagimet Biosciences's current ratio?
Sagimet Biosciences's current ratio was 22.82 at the end of fiscal 2025: current assets were 22.82 times current liabilities.